| * |
|
Network: (101 - Statement - Statement Of Income Alternative) |
| 1 |
|
us-gaap: Income Statement [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:IncomeStatementAbstract |
| 2 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 3 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 4 |
|
us-gaap: EARNINGS
|
xbrli:stringItemType |
duration |
|
us-gaap:RevenuesAbstract |
| 5 |
|
us-gaap: Net Sales
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:SalesRevenueNet |
| 6 |
|
us-gaap: Cost of products sold
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:CostOfGoodsSold |
| 7 |
|
us-gaap: Marketing, selling and administrative
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:SellingGeneralAndAdministrativeExpense |
| 8 |
|
us-gaap: Advertising and product promotion
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:MarketingAndAdvertisingExpense |
| 9 |
|
us-gaap: Research and development
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ResearchAndDevelopmentExpense |
| 10 |
|
us-gaap: Acquired in-process research and development
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ResearchAndDevelopmentInProcess |
| 11 |
|
us-gaap: Provision for restructuring, net
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:RestructuringCharges |
| 12 |
|
bmy: Litigation expense, net
|
xbrli:monetaryItemType |
duration |
debit |
bmy:LitigationExpense |
| 13 |
|
us-gaap: Equity in net income of affiliates
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncomeLossFromEquityMethodInvestments |
| 14 |
|
us-gaap: Other (income)/expense, net
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherNonoperatingIncomeExpense |
| 15 |
|
us-gaap: Total Expenses, net
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:CostsAndExpenses |
| 16 |
|
us-gaap: Earnings from Continuing Operations Before Income Taxes
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments |
| 17 |
|
us-gaap: Provision for income taxes
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:IncomeTaxExpenseBenefit |
| 18 |
|
us-gaap: Net Earnings from Continuing Operations
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest |
| 19 |
|
us-gaap: Net Earnings from Discontinued Operations
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax |
| 20 |
|
us-gaap: Net Earnings
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:ProfitLoss |
| 21 |
|
us-gaap: Net Earnings Attributable to Noncontrolling Interest
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest |
| 22 |
|
us-gaap: Net Earnings Attributable to Bristol-Myers Squibb Company
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:NetIncomeLoss |
| 23 |
|
bmy: Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company:
|
xbrli:stringItemType |
duration |
|
bmy:EarningsPerShareFromContinuingOperationsAbstract |
| 24 |
|
us-gaap: Basic
|
us-types:perShareItemType |
duration |
|
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare |
| 25 |
|
us-gaap: Diluted
|
us-types:perShareItemType |
duration |
|
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare |
| 26 |
|
us-gaap: Earnings per Common Share Attributable to Bristol-Myers Squibb Company:
|
xbrli:stringItemType |
duration |
|
us-gaap:EarningsPerShareAbstract |
| 27 |
|
us-gaap: Basic
|
us-types:perShareItemType |
duration |
|
us-gaap:EarningsPerShareBasic |
| 28 |
|
us-gaap: Diluted
|
us-types:perShareItemType |
duration |
|
us-gaap:EarningsPerShareDiluted |
| 29 |
|
us-gaap: Dividends declared per common share
|
us-types:perShareItemType |
duration |
|
us-gaap:CommonStockDividendsPerShareDeclared |
| * |
|
Network: (102 - Statement - Statement Of Other Comprehensive Income) |
| 30 |
|
us-gaap: Statement of Income and Comprehensive Income [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementOfIncomeAndComprehensiveIncomeAbstract |
| 31 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 32 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 33 |
|
us-gaap: COMPREHENSIVE INCOME
|
xbrli:stringItemType |
duration |
|
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract |
| 34 |
|
us-gaap: Net earnings
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:ProfitLoss |
| 35 |
|
us-gaap: Other Comprehensive Income/(Loss):
|
xbrli:stringItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract |
| 36 |
|
us-gaap: Foreign currency translation
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease |
| 37 |
|
us-gaap: Foreign currency translation on hedge of a net investment
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax |
| 38 |
|
us-gaap: Derivatives qualifying as cash flow hedges, net of taxes of $20 and $22 for the three months ended September 30, 2009 and
2008, respectively; and $18 and $3 for the nine months ended September 30, 2009 and 2008, respectively
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease |
| 39 |
|
us-gaap: Derivatives qualifying as cash flow hedges reclassified to net earnings, net of taxes of $1 and $8 for the three months ended
September 30, 2009 and 2008, respectively; and $15 and $24 for the nine months ended September 30, 2009 and 2008, respectively
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax |
| 40 |
|
us-gaap: Pension and postretirement benefits, net of taxes of $220 and $9 for the nine months ended September 30, 2009 and 2008, respectively
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecrease |
| 41 |
|
us-gaap: Pension and postretirement benefits reclassified to net earnings, net of taxes of $4 and $22 for the three months ended September
30, 2009 and 2008, respectively; and $41 and $39 for the nine months ended September 30, 2009 and 2008, respectively
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostNetOfTax |
| 42 |
|
us-gaap: Available for sale securities, net of taxes of $2 and $5 for the three months ended September 30, 2009 and 2008, respectively;
and $3 and $5 for the nine months ended September 30, 2009 and 2008, respectively
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecrease |
| 43 |
|
us-gaap: Available for sale securities reclassified to net earnings, net of taxes of $6 for both the three and nine month periods ended
September 30, 2008
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax |
| 44 |
|
us-gaap: Total Other Comprehensive Income/(Loss)
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease |
| 45 |
|
us-gaap: Comprehensive Income
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest |
| 46 |
|
us-gaap: Comprehensive Income Attributable to Noncontrolling Interest
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
| 47 |
|
us-gaap: Comprehensive Income Attributable to Bristol-Myers Squibb Company
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:ComprehensiveIncomeNetOfTax |
| * |
|
Network: (103 - Statement - Statement Of Other Comprehensive Income (Parenthetical)) |
| 48 |
|
us-gaap: Statement of Income and Comprehensive Income [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementOfIncomeAndComprehensiveIncomeAbstract |
| 49 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 50 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 51 |
|
us-gaap: Derivatives qualifying as cash flow hedges, taxes
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecrease |
| 52 |
|
us-gaap: Derivatives qualifying as cash flow hedges reclassified to net earnings, taxes
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax |
| 53 |
|
us-gaap: Pension and postretirement benefits, taxes
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTax |
| 54 |
|
us-gaap: Pension and postretirement benefits reclassified to net earnings, taxes
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherComprehensiveIncomeReclassificationOfDefinedBenefitPlansNetGainLossRecognizedInNetPeriodicBenefitCostTax |
| 55 |
|
us-gaap: Available for sale securities, taxes
|
xbrli:monetaryItemType |
duration |
|
us-gaap:OtherComprehensiveIncomeAvailableForSaleSecuritiesTax |
| 56 |
|
us-gaap: Available for sale securities reclassified to net earnings, taxes
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax |
| * |
|
Network: (104 - Disclosure - Retained Earnings Table) |
| 57 |
|
bmy: The BMY Custom Retained Earnings Table
|
xbrli:stringItemType |
duration |
|
bmy:RetainedEarningsTableAbstract |
| 58 |
|
us-gaap: RETAINED EARNINGS
|
xbrli:stringItemType |
duration |
|
us-gaap:RetainedEarningsAccumulatedDeficitAbstract |
| 59 |
|
us-gaap: Retained Earnings at January 1
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:RetainedEarningsAccumulatedDeficit |
| 60 |
|
us-gaap: Net Earnings Attributable to Bristol-Myers Squibb Company
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:NetIncomeLoss |
| 61 |
|
us-gaap: Cash dividends declared
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:DividendsCash |
| 62 |
|
us-gaap: Retained Earnings at September 30
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:RetainedEarningsAccumulatedDeficit |
| * |
|
Network: (105 - Statement - Statement Of Financial Position Classified) |
| 63 |
|
us-gaap: Statement of Financial Position [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementOfFinancialPositionAbstract |
| 64 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 65 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 66 |
|
us-gaap: ASSETS
|
xbrli:stringItemType |
duration |
|
us-gaap:AssetsAbstract |
| 67 |
|
us-gaap: Current Assets:
|
xbrli:stringItemType |
duration |
|
us-gaap:AssetsCurrentAbstract |
| 68 |
|
us-gaap: Cash and cash equivalents
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:CashAndCashEquivalentsAtCarryingValue |
| 69 |
|
us-gaap: Marketable securities
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:MarketableSecuritiesCurrent |
| 70 |
|
us-gaap: Receivables, net of allowances of $127 in 2009 and $128 in 2008
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:ReceivablesNetCurrent |
| 71 |
|
us-gaap: Inventories, net
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:InventoryNet |
| 72 |
|
us-gaap: Deferred income taxes, net of valuation allowances
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:DeferredTaxAssetsNetCurrent |
| 73 |
|
us-gaap: Prepaid expenses
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:PrepaidExpenseCurrent |
| 74 |
|
us-gaap: Total Current Assets
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:AssetsCurrent |
| 75 |
|
us-gaap: Property, plant and equipment, net
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:PropertyPlantAndEquipmentNet |
| 76 |
|
us-gaap: Goodwill
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:Goodwill |
| 77 |
|
us-gaap: Other intangible assets, net
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:IntangibleAssetsNetExcludingGoodwill |
| 78 |
|
us-gaap: Deferred income taxes, net of valuation allowances
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:DeferredTaxAssetsNetNoncurrent |
| 79 |
|
us-gaap: Marketable securities
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:MarketableSecuritiesNoncurrent |
| 80 |
|
us-gaap: Other assets
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:OtherAssetsNoncurrent |
| 81 |
|
us-gaap: Total Assets
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:Assets |
| 82 |
|
us-gaap: LIABILITIES
|
xbrli:stringItemType |
duration |
|
us-gaap:LiabilitiesAbstract |
| 83 |
|
us-gaap: Current Liabilities:
|
xbrli:stringItemType |
duration |
|
us-gaap:LiabilitiesCurrentAbstract |
| 84 |
|
us-gaap: Short-term borrowings
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:ShortTermBorrowings |
| 85 |
|
us-gaap: Accounts payable
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AccountsPayableCurrent |
| 86 |
|
us-gaap: Accrued expenses
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AccruedLiabilitiesCurrent |
| 87 |
|
us-gaap: Deferred income
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:DeferredRevenueCurrent |
| 88 |
|
bmy: Accrued rebates and returns
|
xbrli:monetaryItemType |
instant |
credit |
bmy:AccruedRebatesAndReturns |
| 89 |
|
us-gaap: U.S. and foreign income taxes payable
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:TaxesPayableCurrent |
| 90 |
|
us-gaap: Dividends payable
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:DividendsPayableCurrent |
| 91 |
|
us-gaap: Accrued litigation liabilities
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:LitigationReserveCurrent |
| 92 |
|
us-gaap: Total Current Liabilities
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:LiabilitiesCurrent |
| 93 |
|
us-gaap: Pension, postretirement and postemployment liabilities
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent |
| 94 |
|
us-gaap: Deferred income
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:DeferredRevenueNoncurrent |
| 95 |
|
us-gaap: U.S. and foreign income taxes payable
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AccruedIncomeTaxesNoncurrent |
| 96 |
|
us-gaap: Other liabilities
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:OtherLiabilitiesNoncurrent |
| 97 |
|
us-gaap: Long-term debt
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:LongTermDebtNoncurrent |
| 98 |
|
us-gaap: Total Liabilities
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:Liabilities |
| 99 |
|
us-gaap: Commitments and contingencies (Note 23)
|
xbrli:stringItemType |
duration |
|
us-gaap:CommitmentsAndContingencies2009 |
| 100 |
|
us-gaap: EQUITY
|
xbrli:stringItemType |
duration |
|
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract |
| 101 |
|
us-gaap: Bristol-Myers Squibb Company Shareholders' Equity:
|
xbrli:stringItemType |
duration |
|
us-gaap:StockholdersEquityAbstract |
| 102 |
|
us-gaap: Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,515
in 2009 and 5,668 in 2008, liquidation value of $50 per share
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:PreferredStockValue |
| 103 |
|
us-gaap: Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2009 and 2008
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:CommonStockValue |
| 104 |
|
us-gaap: Capital in excess of par value of stock
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AdditionalPaidInCapital |
| 105 |
|
bmy: Restricted stock
|
xbrli:monetaryItemType |
instant |
credit |
bmy:RestrictedStock |
| 106 |
|
us-gaap: Accumulated other comprehensive loss
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax |
| 107 |
|
us-gaap: Retained earnings
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:RetainedEarningsAccumulatedDeficit |
| 108 |
|
us-gaap: Less cost of treasury stock -224 million common shares in 2009 and 226 million in 2008
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:TreasuryStockValue |
| 109 |
|
us-gaap: Total Bristol-Myers Squibb Company Shareholders' Equity
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:StockholdersEquity |
| 110 |
|
us-gaap: Noncontrolling interest
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:MinorityInterest |
| 111 |
|
us-gaap: Total Equity
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
| 112 |
|
us-gaap: Total Liabilities and Equity
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:LiabilitiesAndStockholdersEquity |
| * |
|
Network: (106 - Statement - Statement Of Financial Position Classified (Parenthetical)) |
| 113 |
|
us-gaap: Statement of Financial Position [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementOfFinancialPositionAbstract |
| 114 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 115 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 116 |
|
us-gaap: Receivables, allowances
|
xbrli:monetaryItemType |
instant |
credit |
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent |
| 117 |
|
us-gaap: Preferred stock, $2 convertible series, par value
|
us-types:perShareItemType |
instant |
|
us-gaap:PreferredStockParOrStatedValuePerShare |
| 118 |
|
us-gaap: Preferred stock, $2 convertible series, Authorized
|
xbrli:sharesItemType |
instant |
|
us-gaap:PreferredStockSharesAuthorized |
| 119 |
|
us-gaap: Preferred stock, $2 convertible series, issued
|
xbrli:sharesItemType |
instant |
|
us-gaap:PreferredStockSharesIssued |
| 120 |
|
us-gaap: Preferred stock, $2 convertible series, outstanding
|
xbrli:sharesItemType |
instant |
|
us-gaap:PreferredStockSharesOutstanding |
| 121 |
|
us-gaap: Preferred stock, $2 convertible series, liquidation value
|
us-types:perShareItemType |
instant |
|
us-gaap:PreferredStockLiquidationPreference |
| 122 |
|
us-gaap: Common stock, par value
|
us-types:perShareItemType |
instant |
|
us-gaap:CommonStockParOrStatedValuePerShare |
| 123 |
|
us-gaap: Common stock, Authorized
|
xbrli:sharesItemType |
instant |
|
us-gaap:CommonStockSharesAuthorized |
| 124 |
|
us-gaap: Common stock, issued
|
xbrli:sharesItemType |
instant |
|
us-gaap:CommonStockSharesIssued |
| 125 |
|
us-gaap: Treasury stock, shares
|
xbrli:sharesItemType |
instant |
|
us-gaap:TreasuryStockShares |
| * |
|
Network: (107 - Statement - Statement Of Cash Flows Indirect) |
| 126 |
|
us-gaap: Statement of Cash Flows [Abstract]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementOfCashFlowsAbstract |
| 127 |
|
us-gaap: Statement [Table]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementTable |
| 128 |
|
us-gaap: Statement [Line Items]
|
xbrli:stringItemType |
duration |
|
us-gaap:StatementLineItems |
| 129 |
|
us-gaap: Cash Flows From Operating Activities:
|
xbrli:stringItemType |
duration |
|
us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract |
| 130 |
|
us-gaap: Net earnings
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:ProfitLoss |
| 131 |
|
us-gaap: Adjustments to reconcile net earnings to net cash provided by operating activities:
|
xbrli:stringItemType |
duration |
|
us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
| 132 |
|
us-gaap: Net earnings attributable to noncontrolling interest
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest |
| 133 |
|
us-gaap: Depreciation
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:Depreciation |
| 134 |
|
us-gaap: Amortization
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:AdjustmentForAmortization |
| 135 |
|
us-gaap: Deferred income tax expense
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:DeferredIncomeTaxExpenseBenefit |
| 136 |
|
us-gaap: Stock-based compensation expense
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ShareBasedCompensation |
| 137 |
|
us-gaap: Impairment charges
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:AssetImpairmentCharges |
| 138 |
|
us-gaap: Gain on sale of product lines and businesses
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
| 139 |
|
bmy: Gain on debt buyback and interest swap terminations
|
xbrli:monetaryItemType |
duration |
debit |
bmy:GainLossOnDebtBuyBackRestructuringAndInterestRateSwapTermination |
| 140 |
|
bmy: (Gain)/Loss on sale of property, plant and equipment and investment in other companies
|
xbrli:monetaryItemType |
duration |
credit |
bmy:RealizedGainLossOnInvestmentsAndPropertyPlantAndEquipment |
| 141 |
|
us-gaap: Acquired in-process research and development
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ResearchAndDevelopmentInProcess |
| 142 |
|
us-gaap: Changes in operating assets and liabilities:
|
xbrli:stringItemType |
duration |
|
us-gaap:IncreaseDecreaseInOperatingCapitalAbstract |
| 143 |
|
us-gaap: Receivables
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncreaseDecreaseInReceivables |
| 144 |
|
us-gaap: Inventories
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncreaseDecreaseInInventories |
| 145 |
|
us-gaap: Deferred income
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:IncreaseDecreaseInDeferredRevenue |
| 146 |
|
us-gaap: Accounts payable
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:IncreaseDecreaseInAccountsPayable |
| 147 |
|
bmy: U.S. and foreign income taxes payable
|
xbrli:monetaryItemType |
duration |
debit |
bmy:IncreaseDecreaseInIncomeTaxesNet |
| 148 |
|
us-gaap: Changes in other operating assets and liabilities
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet |
| 149 |
|
us-gaap: Net Cash Provided by Operating Activities
|
xbrli:monetaryItemType |
duration |
|
us-gaap:NetCashProvidedByUsedInOperatingActivities |
| 150 |
|
us-gaap: Cash Flows From Investing Activities:
|
xbrli:stringItemType |
duration |
|
us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract |
| 151 |
|
us-gaap: Proceeds from sale of marketable securities
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities |
| 152 |
|
us-gaap: Purchases of marketable securities
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:PaymentsToAcquireMarketableSecurities |
| 153 |
|
us-gaap: Additions to property, plant and equipment and capitalized software
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| 154 |
|
us-gaap: Proceeds from sale of property, plant and equipment and investment in other companies
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment |
| 155 |
|
us-gaap: Proceeds from sale of product lines and businesses
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromDivestitureOfBusinesses |
| 156 |
|
us-gaap: Purchase of Medarex, Inc, net of cash acquired
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired |
| 157 |
|
bmy: Purchase of Kosan Biosciences, Inc, net of cash acquired
|
xbrli:monetaryItemType |
duration |
debit |
bmy:CashPaidForAcquiredBusinessesNetOfCashAcquired |
| 158 |
|
bmy: Proceeds from sale and leaseback of properties
|
xbrli:monetaryItemType |
duration |
debit |
bmy:ProceedsFromTheSaleLeasebackOfPremises |
| 159 |
|
us-gaap: Net Cash (Used in)/Provided by Investing Activities
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:NetCashProvidedByUsedInInvestingActivities |
| 160 |
|
us-gaap: Cash Flows From Financing Activities:
|
xbrli:stringItemType |
duration |
|
us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract |
| 161 |
|
us-gaap: Short-term debt repayments
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromRepaymentsOfShortTermDebt |
| 162 |
|
us-gaap: Long-term debt borrowings
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromIssuanceOfLongTermDebt |
| 163 |
|
us-gaap: Long-term debt repayments
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:RepaymentsOfLongTermDebt |
| 164 |
|
bmy: Interest rate swap termination
|
xbrli:monetaryItemType |
duration |
debit |
bmy:ProceedsTerminationInterestRateSwap |
| 165 |
|
us-gaap: Issuances of common stock under stock plans and excess tax benefits from share-based payment arrangements
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans |
| 166 |
|
us-gaap: Dividends paid
|
xbrli:monetaryItemType |
duration |
credit |
us-gaap:PaymentsOfDividends |
| 167 |
|
us-gaap: Proceeds from Mead Johnson initial public offering
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:ProceedsFromIssuanceOrSaleOfEquity |
| 168 |
|
us-gaap: Net Cash Used in Financing Activities
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:NetCashProvidedByUsedInFinancingActivities |
| 169 |
|
us-gaap: Effect of Exchange Rates on Cash and Cash Equivalents
|
xbrli:monetaryItemType |
duration |
debit |
us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents |
| 170 |
|
us-gaap: (Decrease)/Increase in Cash and Cash Equivalents
|
xbrli:monetaryItemType |
duration |
|
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease |
| 171 |
|
us-gaap: Cash and Cash Equivalents at Beginning of Period
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:CashAndCashEquivalentsAtCarryingValue |
| 172 |
|
us-gaap: Cash and Cash Equivalents at End of Period
|
xbrli:monetaryItemType |
instant |
debit |
us-gaap:CashAndCashEquivalentsAtCarryingValue |
| * |
|
Network: (108 - Disclosure - Note 1. Basis of Presentation and New Accounting Standards) |
| 173 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 174 |
|
bmy: Note 1. Basis of Presentation and New Accounting Standards
|
us-types:textBlockItemType |
duration |
|
bmy:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock |
| * |
|
Network: (109 - Disclosure - Note 2. Alliances and Collaborations) |
| 175 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 176 |
|
us-gaap: Note 2. Alliances and Collaborations
|
us-types:textBlockItemType |
duration |
|
us-gaap:CollaborativeArrangementDisclosureTextBlock |
| * |
|
Network: (110 - Disclosure - Note 3. Business Segments) |
| 177 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 178 |
|
us-gaap: Note 3. Business Segments
|
us-types:textBlockItemType |
duration |
|
us-gaap:SegmentReportingDisclosureTextBlock |
| * |
|
Network: (111 - Disclosure - Note 4. Restructuring) |
| 179 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 180 |
|
us-gaap: Note 4. Restructuring
|
us-types:textBlockItemType |
duration |
|
us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock |
| * |
|
Network: (112 - Disclosure - Note 5. Medarex, Inc. Acquisition) |
| 181 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 182 |
|
us-gaap: Note 5. Medarex, Inc. Acquisition
|
us-types:textBlockItemType |
duration |
|
us-gaap:BusinessCombinationDisclosureTextBlock |
| * |
|
Network: (113 - Disclosure - Note 6. Mead Johnson Nutrition Company Initial Public Offering) |
| 183 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 184 |
|
bmy: Note 6. Mead Johnson Nutrition Company Initial Public Offering
|
us-types:textBlockItemType |
duration |
|
bmy:MeadJohnsonIPOTextBlock |
| * |
|
Network: (114 - Disclosure - Note 7. Discontinued Operations) |
| 185 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 186 |
|
us-gaap: Note 7. Discontinued Operations
|
us-types:textBlockItemType |
duration |
|
us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock |
| * |
|
Network: (115 - Disclosure - Note 8. Earnings Per Share) |
| 187 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 188 |
|
us-gaap: Note 8. Earnings Per Share
|
us-types:textBlockItemType |
duration |
|
us-gaap:EarningsPerShareTextBlock |
| * |
|
Network: (116 - Disclosure - Note 9. Other (Income)/Expense, Net) |
| 189 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 190 |
|
us-gaap: Note 9. Other (Income)/Expense, Net
|
us-types:textBlockItemType |
duration |
|
us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock |
| * |
|
Network: (117 - Disclosure - Note 10. Income Taxes) |
| 191 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 192 |
|
us-gaap: Note 10. Income Taxes
|
us-types:textBlockItemType |
duration |
|
us-gaap:IncomeTaxDisclosureTextBlock |
| * |
|
Network: (118 - Disclosure - Note 11. Fair Value Measurement) |
| 193 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 194 |
|
us-gaap: Note 11. Fair Value Measurement
|
us-types:textBlockItemType |
duration |
|
us-gaap:FairValueMeasurementInputsDisclosureTextBlock |
| * |
|
Network: (119 - Disclosure - Note 12. Cash, Cash Equivalents and Marketable Securities) |
| 195 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 196 |
|
us-gaap: Note 12. Cash, Cash Equivalents and Marketable Securities
|
us-types:textBlockItemType |
duration |
|
us-gaap:CashAndCashEquivalentsDisclosureTextBlock |
| * |
|
Network: (120 - Disclosure - Note 13. Receivables, Net) |
| 197 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 198 |
|
us-gaap: Note 13. Receivables, Net
|
us-types:textBlockItemType |
duration |
|
us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock |
| * |
|
Network: (121 - Disclosure - Note 14. Inventories, Net) |
| 199 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 200 |
|
us-gaap: Note 14. Inventories, Net
|
us-types:textBlockItemType |
duration |
|
us-gaap:InventoryDisclosureTextBlock |
| * |
|
Network: (122 - Disclosure - Note 15. Property, Plant and Equipment, Net) |
| 201 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 202 |
|
us-gaap: Note 15. Property, Plant and Equipment, Net
|
us-types:textBlockItemType |
duration |
|
us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock |
| * |
|
Network: (123 - Disclosure - Note 16. Accrued Expenses) |
| 203 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 204 |
|
bmy: Note 16. Accrued Expenses
|
us-types:textBlockItemType |
duration |
|
bmy:AccruedLiabilitiesDisclosureTextBlock |
| * |
|
Network: (124 - Disclosure - Note 17. Goodwill and Other Intangible Assets) |
| 205 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 206 |
|
us-gaap: Note 17. Goodwill and Other Intangible Assets
|
us-types:textBlockItemType |
duration |
|
us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock |
| * |
|
Network: (125 - Disclosure - Note 18. Equity) |
| 207 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 208 |
|
bmy: Note 18. Equity
|
us-types:textBlockItemType |
duration |
|
bmy:EquityNoteDisclosureTextBlock |
| * |
|
Network: (126 - Disclosure - Note 19. Pension, Postretirement and Postemployment Liabilities) |
| 209 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 210 |
|
us-gaap: Note 19. Pension, Postretirement and Postemployment Liabilities
|
us-types:textBlockItemType |
duration |
|
us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock |
| * |
|
Network: (127 - Disclosure - Note 20. Employee Stock Benefit Plans) |
| 211 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 212 |
|
us-gaap: Note 20. Employee Stock Benefit Plans
|
us-types:textBlockItemType |
duration |
|
us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock |
| * |
|
Network: (128 - Disclosure - Note 21. Short-Term Borrowings and Long-Term Debt) |
| 213 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 214 |
|
us-gaap: Note 21. Short-Term Borrowings and Long-Term Debt
|
us-types:textBlockItemType |
duration |
|
us-gaap:DebtDisclosureTextBlock |
| * |
|
Network: (129 - Disclosure - Note 22. Financial Instruments) |
| 215 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 216 |
|
us-gaap: Note 22. Financial Instruments
|
us-types:textBlockItemType |
duration |
|
us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock |
| * |
|
Network: (130 - Disclosure - Note 23. Legal Proceedings and Contingencies) |
| 217 |
|
bmy: Notes to Financial Statements [Abstract]
|
xbrli:stringItemType |
duration |
|
bmy:NotesToFinancialStatementsAbstract |
| 218 |
|
bmy: Note 23. Legal Proceedings and Contingencies
|
us-types:textBlockItemType |
duration |
|
bmy:ContingenciesDisclosureTextBlock |
| * |
|
Network: (131 - Disclosure - Document Information) |
| 219 |
|
dei: Document Information [Text Block]
|
us-types:textBlockItemType |
duration |
|
dei:DocumentInformationTextBlock |
| 220 |
|
dei: Document Type
|
us-types:SECReportItemType |
duration |
|
dei:DocumentType |
| 221 |
|
dei: Amendment Flag
|
xbrli:booleanItemType |
duration |
|
dei:AmendmentFlag |
| 222 |
|
dei: Document Period End Date
|
xbrli:dateItemType |
duration |
|
dei:DocumentPeriodEndDate |
| * |
|
Network: (132 - Disclosure - Entity Information) |
| 223 |
|
dei: Entity [Text Block]
|
us-types:textBlockItemType |
duration |
|
dei:EntityTextBlock |
| 224 |
|
dei: Trading Symbol
|
xbrli:normalizedStringItemType |
duration |
|
dei:TradingSymbol |
| 225 |
|
dei: Entity Registrant Name
|
xbrli:normalizedStringItemType |
duration |
|
dei:EntityRegistrantName |
| 226 |
|
dei: Entity Central Index Key
|
us-types:centralIndexKeyItemType |
duration |
|
dei:EntityCentralIndexKey |
| 227 |
|
dei: Current Fiscal Year End Date
|
xbrli:gMonthDayItemType |
duration |
|
dei:CurrentFiscalYearEndDate |
| 228 |
|
dei: Entity Filer Category
|
us-types:filerCategoryItemType |
duration |
|
dei:EntityFilerCategory |
| 229 |
|
dei: Entity Common Stock, Shares Outstanding
|
xbrli:sharesItemType |
instant |
|
dei:EntityCommonStockSharesOutstanding |